Looking for collaboration, funding and support opportunities for your rare disease research? Explore Raremap to find the connections you need: raremap.co.uk/

Why should investors pay more attention to rare diseases? During his panel, Chris Molloy shares why the sector offers both patient impact and commercial value. Watch the recording from #LATSS2026, plus 30+ other sessions, on our YouTube channel: youtu.be/ZbrD0yq0idg?...

This week, @telegraph.co.uk explored how ASPIRE, a programme we support through our partnership with @reactgroup.bsky.social, is strengthening antimicrobial stewardship across Zambia and Kenya. Read now: www.telegraph.co.uk/global-healt...

Imaging is one of the most powerful tools for drug discovery, allowing us to see biology in action. Here, Becca from our imaging team shows us how we quality-check neurons generated from our in-house induced pluripotent stem cell capability.

Drug-resistant infections are a global challenge. GAMRIC brings together the people developing the solutions. Join the #AMR community in Lisbon this September for three days of discussion, collaboration and new ideas. Register today 👉 gamric.org

In a letter published today in the @financialtimes.com, our CEO Sam Barrell welcomes increased investment in rare diseases while arguing that much more needs to be done to bring new treatments to patients. www.ft.com/content/d365...

Letter: UK can lead way on rare disease treatments

From Sam Barrell, CEO of LifeArc, London WC1H, UK

ft.com

Is your organisation on Raremap yet? Join the living resource that makes the UK rare disease landscape easier to navigate. Visit Raremap now and request to be added: raremap.co.uk/join/

A decade after her daughter Mila received the first medicine designed for a single individual, Julia Vitarello explains what’s needed to make individualised medicines accessible to all. Watch this #LATSS2026 session and 30+ more on our YouTube channel: https://bit.ly/3TkAuKb

Drug-resistant infections pose a huge global health challenge. This week, we were in Zambia at the ReAct Africa Annual AMR Conference and to meet the ASPIRE programme team, working for better-informed antibiotic prescription decisions. Find out more: t.ly/LcRUQ

We brought together clinicians, researchers and patient advocates to prioritise new treatment approaches for medulloblastoma. For high-risk disease, we focused on tumour ‘drivers’; for lower-risk subtypes, on opportunities for kinder, antibody-based treatments. 🔗https://t.ly/dE8h-

It's brilliant to have so many organisations joining Raremap. If you work in rare diseases and are not part of the directory yet, apply to be added now.

Oxford-Harrington Rare Disease Centre@oxfordharrington.bsky.social · 2w ago

We're delighted to be included on Raremap, a new guide to the UK's rare disease research ecosystem developed by @lifearc.bsky.social and @rdrukhub.bsky.social. Explore: 🔗 : buff.ly/yQx6pYT #RareDiseases #RareDiseaseResearch

What would it take to make cancer non-lethal within our lifetime? Reed Jobs, Founder of Yosemite, explores how his venture capital firm is helping accelerate the next generation of cancer breakthroughs. Watch 30+ #LATSS2026 sessions on our YouTube channel: www.youtube.com/watch?v=aLRS...

(Opening Plenary) A new model for oncology innovation: how Yosemite funds what matters | LATSS 2026

YouTube video by LifeArc

youtube.com

The UK has been at the forefront of many scientific and medical breakthroughs over the past century. So we're proud to be featured in Monarchy and Democracy: A History of Leadership, which showcases organisations that have contributed to leadership and progress in the UK.

Rare disease affects millions of people worldwide, but making progress can be hindered by small numbers. That's where Our Future Health comes in. Read more about how this rich dataset is helping change the outlook for people with rare diseases: https://t.ly/TdkjX

The rare disease landscape can be complex to navigate – that's why we've collaborated with @rdrukhub.bsky.social to launch Raremap. It's a searchable directory of rare disease organisations so you can find out who does what and how to connect. Visit Raremap now: https://t.ly/nY3Rz

12 childhood cancers. 12 workshops. 24 months. We've just hosted the final Paediatric Therapeutic Development Workshop – a major milestone towards new treatment options for childhood cancers with the greatest unmet need. Read more: https://t.ly/SO81e

"A hospital admission can be a major setback for someone with dementia. If we can spot problems earlier and help people stay safely at home, that has the potential to change lives, not just ease pressure on health services," says our CEO Sam Barrell in today's @express.co.uk

We're pleased to announce that over 30 recordings from #LATSS2026 are now available. If you weren't able to attend, or would like to revisit any of the sessions, you can explore them at your leisure on our YouTube channel: https://t.ly/OygJ3

Between 60–70% of medulloblastoma patients survive, but many face long-term side effects. For the highest-risk groups, survival is below 10%. Our workshop identified new treatment approaches to help address these urgent unmet needs for children. 🔗 Read more: t.ly/g5-qs

The first edition of the Global AMR Innovators Conference left a lasting impression. #GAMRIC2026 is coming to Lisbon in September – find out more and register now: gamric.org/

Our new partnership with University of Birmingham will see us developing a new targeted antibody for autoimmune diseases with our B-SMArT platform. An exciting step forward in finding safer, more targeted treatment options for patients.

At the LifeArc Translational Science Summit, our CEO Sam Barrell reflected on the importance of bringing together the translational community and why the UK is so well-placed to advance treatments for people living with rare diseases. #LATSS2026

"Science is no longer the limiting factor. The system is." That idea echoed through #LATSS2026 where life sciences experts came together to explore speeding up patient impact through collaboration. Read the highlights now: https://t.ly/pVDrg

LifeArc Translational Science Summit 2026: Charting new paths for rare disease  - LifeArc

On 12 May, the LifeArc Translational Science Summit (LATSS) convened 700 stakeholders from research, healthcare, industry, investment, policy and the patient community to focus on one shared challenge...

t.ly

AI has the power to transform brain health, but only if it works for everyone. Most AI models are built on Global North datasets, yet 71% of dementia cases will be in low and middle-resource settings by 2050. We explore why equity matters and more in our recent blog. Read now: https://t.ly/p1e3F

The future of brain health: Early detection, equity and systematic change  - LifeArc

The brain is the foundation of how we live, work, and connect and as societies age, the burden of brain-health conditions is rapidly rising. By 2050, more than 2.1 billion people will be over the age ...

t.ly

Today is #WorldMicrobiomeDay! We spoke to early career researchers Heritage and Lillie to find out more about the LUNG microbiome and why they’re studying it to improve treatments for CF lung infections. ➡️ https://ow.ly/nBox50ZhuyN #PrecisionCF LifeArc #cysticfibrosis #cftrust

Some stories stay with you. In this video, Angela shares her family’s heartbreaking experience with childhood cancer. It’s a deeply moving reminder of the urgent need to advance research and development of new treatments: https://t.ly/qp45C

"It's something no family should go through" | Why we work in childhood cancer

Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

t.ly

Could we fix some disorders of the immune system by editing a patient's own cells? We're supporting a new study to treat CTLA-4 insufficiency using gene editing technology. Dr Thomas Fox, Principal Investigator for the trial, tells us more. Read more: t.ly/Wl7wL

We’re really pleased to welcome the Rare Therapies Launch Pad (RTLP) into LifeArc. RTLP has built a collaborative community focused on a shared challenge: how to turn advances in genetics into treatments that can reach individual patients.

We’re sponsoring National Patient Data Day 2026, led by @usemydata.bsky.social. Join webinars tomorrow to celebrate the use of patient data and discuss how to ensure that health data is used to save lives and improve outcomes for all. Register now: https://bit.ly/3Rkuvny #NPaDD2026

Drug-resistant infections threaten decades of medical progress. As the crisis worsens, we've formed partnerships to support innovators, remove barriers and help new tests and treatments reach patients sooner. 🔗Learn more about our partnerships: https://t.ly/1wlAB #AMR